Sign in

    Matt Dellatorre

    Vice President and Equity Analyst at Goldman Sachs

    Matt Dellatorre is a Vice President and Equity Analyst at Goldman Sachs, specializing in coverage of the generic pharmaceuticals and biotechnology sectors. He formally covers companies such as Viatris and has issued ratings including a recent 'Neutral' initiation, though his tracked performance metrics indicate a 0% success rate and an average return of -7.5% over the last rating cycle. Dellatorre began his analyst career at Goldman Sachs in 2020 after earning a doctorate degree, and previously worked as an Associate before advancing to his current leadership role. He holds professional FINRA registrations and securities licenses, including CRD# 7174007, and is based out of Goldman Sachs’s Washington, DC office.

    Matt Dellatorre's questions to Viatris (VTRS) leadership

    Matt Dellatorre's questions to Viatris (VTRS) leadership • Q2 2025

    Question

    Matt Dellatorre of Goldman Sachs inquired about Viatris's capital allocation strategy, the balance between share buybacks and business development (BD), and the company's long-term growth targets for 2026 and beyond.

    Answer

    CEO Scott Smith stated that the capital allocation plan remains balanced between shareholder returns and strategic, accretive BD to build a growth portfolio. He highlighted upcoming product launches and pipeline readouts as key organic growth drivers, declining to provide a specific 2026 growth target. CFO Doretta Mistras added that the base business is expected to generate low single-digit revenue growth, with BD investments being additive to that baseline.

    Ask Fintool Equity Research AI